Contrast developer Mallinckrodt has received Food and Drug Administration approval for a new version of its OptiMark MRI contrast media that can be administered via power injection. According to the FDA, the OptiMark injection should be administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) at a rate of 1-2 mL/second delivered manually or by power injection.
The contrast media is packaged in plastic UltraJect pre-filled syringes and is compatible with the firm’s OptiStar LE injector. It is also available in glass vials in a range of sizes, according to Hazelwood, MO-based Mallinckrodt.
By AuntMinnie.com staff writers
March 18, 2003
Related Reading
Mallinckrodt adds to contrast injector line, December 1, 2002
Palatin, Mallinckrodt restructure deal, May 15, 2002
Copyright © 2003 AuntMinnie.com
